Taro Pharmaceutical Industries Ltd (TARO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
Jul 26, 2022: Taro to Release First Quarter Results on July 27, 2022
Jul 26, 2022: Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2022
May 28, 2022: Taro Provides Results for the Year Ended March 31, 2022
May 20, 2022: Taro to Announce Full Year Results on May 26, 2022
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Gain key insights into the company for academic or business research.
The profile contains critical company information including:
- Business description - A detailed description of the company's operations and business divisions.
- Corporate strategy - Analyst's summarization of the company's business strategy.
- SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Taro Pharmaceutical Industries Ltd (Taro) discovers, develops and markets healthcare products. The company manufactures prescription drugs, non-prescription drugs and active pharmaceutical ingredients (APIs). It develops pharmaceutical products in semi-solids formulations, such as ointments and creams and other dosage forms including liquids, capsules and tablets. Taro develops products in dermatological and topical, neuropsychiatric, anti-inflammatory and cardiovascular areas. The company sells and distributes its product to healthcare institutions, drug store chains, and private pharmacies. It has presence in Israel, the US, Canada and other countries. The company markets over 200 pharmaceutical products in more than 25 countries worldwide. Taro is headquartered in Haifa Bay, Israel.Taro Pharmaceutical Industries Ltd Key Recent Developments
Jul 27, 2022: Taro Provides Results for the Quarter Ended June 30, 2022Jul 26, 2022: Taro to Release First Quarter Results on July 27, 2022
Jul 26, 2022: Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2022
May 28, 2022: Taro Provides Results for the Year Ended March 31, 2022
May 20, 2022: Taro to Announce Full Year Results on May 26, 2022
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer Inc
- Perrigo Co Plc
- Novartis AG
- Janssen Inc
- GSK plc
- Bayer Inc
- Bausch Health Companies Inc
- Apotex Inc
- Eli Lilly and Co
- Viatris Inc
- Merck & Co Inc
- Glenmark Pharmaceuticals Inc
- Dexcel Pharma Technologies, Ltd.
- Celgene Corp
- Teva Pharmaceutical Industries Ltd
- Galderma Laboratories LP
- Rafa Laboratories Co Ltd
- Pharmascience Inc
- Bristol-Myers Squibb Co
- Valeant Canada Ltd